We should not only validate the aberrant expression of KRT80 in more cancers and its role as a cancer‐promoting oncogene, but also focus on the study of KRT80‐related upstream and downstream regulatory molecules and pathways, for example, there are many gaps that have not been filled in Table 2. This evidence concerns the gene KRT80 and cancer.